The Weekly Roundup: December 31-January 5

Looking Ahead to 2024 Dermatology Drug Approvals

Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.

Dermatology Times' 2024 Health Awareness Calendar of Dates

Click here to view Dermatology Times' comprehensive list of health awareness days, months, weeks, and initiatives for 2024.

POLL: What Are Your 2024 Dermatology Resolutions?

Click here to answer this week's poll.

Dermatology Conferences and Meetings Calendar 2024: January

Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.

QUIZ: Test Your Psoriasis Knowledge

Test your knowledge of psoriasis treatment options with our 5-question quiz.

Examining Rates of Conjunctivitis in Dupilumab-Treated Patients

A late breaking session from Revolutionizing Atopic Dermatitis Virtual Conference analyzed the frequency and clinical meaningfulness of conjunctivitis.

3 Things You Should Know About the Pathogenesis and Treatment of HS

This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.

A Holiday Message from the President of SDPA

The work we do as caregivers is important, and it's equally important that we take care of ourselves.

Phase 2a Study Demonstrates Dose-Dependent Tolerability of Oral Orismilast in Hidradenitis Suppurativa

Results of this study may also be indicative of oral orismilast's ability to contribute to meaningful clinical improvements, investigators noted.

Pointers With Portela: 5 Essential Acne Care Tips

In this week’s Pointers With Portela, the 208SkinDoc reveals his 5 essential acne care tips.

Medicus Pharma Submits Phase 2 IND Clinical Protocol to FDA to Non-Invasively Treat BCC

SKNJCT-003 is expected to enroll up to 60 patients.

Paul Friedman, MD: An In-Depth Review of UltraClear Laser-Coring

Paul Friedman, MD, discusses the benefits of UltraClear Laser-Coring, patient downtime, how to decide what devices to have in your clinic, and more.

Krystal Biotech Receives Permanent J-code for B-VEC for the Treatment of DEB

J3401 went into effect on January 1, 2024.

CareFirst Files Lawsuit Against J&J Over Delay Tactics for Stelara Biosimilars

While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.

FDA Accepts Accord BioPharma's BLA for Proposed Ustekinumab Biosimilar DMB-3115

The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.

Verrica Shares Details From FDA Meeting for Clinical Development of Ycanth in Warts

The Type C meeting held this past December involved discussion of a phase 3 clinical development plan for Ycanth in the treatment of common warts.

Phase 2a Study of Synthetic Hypericin for Mild to Moderate Psoriasis Yields Clinical Success

Soligenix shared today positive top-line data stemming from the phase 2a clinical trial.

Novel, Nonsurgical BCC Treatment Shown Safe and Effective

In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.

Journey Submits New Drug Application for DFD-29 for Rosacea

The filing is supported by positive phase 3 clinical trial data.

Retinoid-Based Regimen Led to Significant Improvements in Skin Clarity Among Patients with Darker, Blemish-Prone Skin

The pilot study explored the use of double-conjugated retinoid serum used in combination with exfoliating peel pads.

Last Patient Dosed in Verrica's Phase 2 Study of VP-315 for Basal Cell Carcinoma

The last patient has been dosed in the trial of the potential first-in-class oncolytic peptide for BCC.

CBP/β-catenin Antagonists: A Safe and Novel Approach for Skin Rejuvenation and Aging

Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.